financetom
Business
financetom
/
Business
/
Disbursement growth of 35-40% annually achievable, says Equitas CEO PN Vasudevan
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Disbursement growth of 35-40% annually achievable, says Equitas CEO PN Vasudevan
May 13, 2019 3:39 AM

Equitas Small Finance Bank reported a mixed bag of fourth quarter numbers.

Throwing further light on the quarterly performance and outlook going forward PN Vasudevan, managing director and CEO of Equitas Small Finance Bank, said the contraction on net interest margins seen in the quarter was due to reduction in yields.

In Q4, there are usually many holidays in January and so microfinance business slows down and in March this year there was slowdown in microfinance and small business loans due to code of conduct announced in different parts of the country, said Vasudevan, adding that this slowdown in disbursements impacted spreads, which were down by 50 basis points between Q3 and Q4.

The contraction in spreads going forward is expected to be offset by reduction in operating expense and NPAs, he said.

Talking about the strong loan growth, he said the growth is spread across products and across geographies. “If you see our asset mix, we have microfinance at 25 percent, commercial vehicle at 25 percent, small business loan at 40 percent and new products at 10 percent — we have range of products which address their own markets for growth.”

He is confident of disbursement growth to be around 35-40 percent annual growth and the only challenge would be that of asset quality. However, as long as they have control over asset quality, growth would continue, he said.

Giving update on the listing, reverse merger and whether there would be any dilution, he said, they are required to list the bank within 3 years, which is by September this year but there is a process and right now they are waiting for the first level approval.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Endeavor Group Agrees to be Acquires by Silver Lake for $13 Billion
Endeavor Group Agrees to be Acquires by Silver Lake for $13 Billion
Apr 2, 2024
12:40 PM EDT, 04/02/2024 (MT Newswires) -- Endeavor Group ( EDR ) , a sports and entertainment company, said Tuesday that it has agreed to be acquired by private equity firm Silver Lake for an equity value of $13 billion. Under the terms of the deal, Silver Lake will acquire all of Endeavor's outstanding shares that it does not already...
Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies; Shares Jump
Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies; Shares Jump
Apr 2, 2024
12:42 PM EDT, 04/02/2024 (MT Newswires) -- Evaxion Biotech ( EVAX ) said Tuesday that three studies showed antigens from its preclinical EVX-B1 vaccine candidate significantly protected large, non-rodent animals against surgical site infections caused by Staphylococcus aureus. The company said it is discussing options to move forward with an unnamed collaborator. Evaxion shares jumped 17% in recent trading. Price:...
Why Aditxt Stock Is Volatile Today
Why Aditxt Stock Is Volatile Today
Apr 2, 2024
Aditxt, Inc. ( ADTX ) shares are volatile Tuesday after the company announced it will acquire Appili Therapeutics. The Details: Aditxt’s wholly owned subsidiary, Adivir, Inc. will acquire all issued and outstanding Class A common shares of Appili in the transaction.  Appili has developed FDA-approved Likmez (previously ATI-1501), its ATI-1701 biodefense program supported by a USD $14 million non-dilutive award...
US takes next step in Medicare drug price negotiations with pharma companies
US takes next step in Medicare drug price negotiations with pharma companies
Apr 2, 2024
WASHINGTON, April 2 (Reuters) - The Biden administration said on Tuesday it has responded to offers from the manufacturers of 10 high-cost drugs selected for the U.S. Medicare program's first-ever pricing negotiations, but provided no details. Part of 2022's Inflation Reduction Act allows Medicare to negotiate prices for prescription drugs that had been particularly expensive for the federal health program...
Copyright 2023-2026 - www.financetom.com All Rights Reserved